Michael Manns

Prof. Michael Manns


Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2001 in The Lancet
Verified
Journal Article
Closed access
MMMichael Manns
Michael Manns
JMJohn G McHutchison
John G McHutchison
SGStuart C Gordon
Stuart C Gordon
VRVinod K Rustgi
Vinod K Rustgi
MSMitchell Shiffman
Mitchell Shiffman
JAJanice K Albrecht
Janice K Albrecht

23 May 2010 in Hepatology
Verified
Journal Article
Open access
PDF file
MMMichael Manns
Michael Manns
ACAlbert J. Czaja
Albert J. Czaja
JGJames D. Gorham
James D. Gorham
EKEdward L. Krawitt
Edward L. Krawitt
GMGiorgina Mieli-Vergani
Giorgina Mieli-Vergani
JVJohn M. Vierling
John M. Vierling

11 August 2006 in Gut
Verified
Journal Article
Closed access
PDF file
MMMichael Manns
Michael Manns
HWH Wedemeyer
H Wedemeyer
MCM Cornberg
M Cornberg
The treatment of hepatitis C has dramatically improved over the past decade. Unlike any other chronic viral infection, a significant proportion of patients with chronic hepatitis C can be cured. However, the current standard therapy--pegylated interferon alpha and ribavirin--has its limitations. Limited efficacy in patients with hepatitis C virus (HCV) genotype 1 and the side effect profile will necessitate the development of new therapeutic approaches. This review describes the efficacy and optimisation of the current standard therapy of hepatitis C and its problems in special patient populations. New treatment directions beyond interferon alpha based therapies are on the horizon.

27 January 2011 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
HWHeiner Wedemeyer
Heiner Wedemeyer
CYCihan Yurdaydìn
Cihan Yurdaydìn
GDGeorge N. Dalekos
George N. Dalekos
AEAndreas Erhardt
Andreas Erhardt
YÇYilmaz Çakaloğlu
Yilmaz Çakaloğlu
MMMichael Manns
Michael Manns
Chronic infection with hepatitis B virus and hepatitis delta virus (HDV) results in the most severe form of viral hepatitis. There is no currently approved treatment. We investigated the safety and efficacy of 48 weeks of treatment with peginterferon alfa-2a plus adefovir dipivoxil, peginterferon alfa-2a alone, and adefovir dipivoxil alone. We conducted a randomized trial in which 31 patients with HDV infection received treatment with 180 μg of peginterferon alfa-2a weekly plus 10 mg of adefovir daily, 29 received 180 μg of peginterferon alfa-2a weekly plus placebo, and 30 received 10 mg of adefovir alone weekly for 48 weeks. Follow-up was conducted for an additional 24 weeks. Efficacy end points included clearance of HDV RNA, normalization of alanine aminotransferase levels, and a decline in levels of hepatitis B surface antigen (HBsAg). The primary end point — normalization of alanine aminotransferase levels and clearance of HDV RNA at week 48 — was achieved in two patients in the group receiving peginterferon alfa-2a plus adefovir and two patients in the group receiving peginterferon alfa-2a plus placebo but in none of the patients in the group receiving adefovir alone. At week 48, the test for HDV RNA was negative in 23% of patients in the first group, 24% of patients in the second, and none of those in the third (P=0.006 for the comparison of the first and third groups; P=0.004 for the comparison of the second and third). The efficacy of peginterferon alfa-2a was sustained for 24 weeks after treatment, with 28% of the patients receiving peginterferon alfa-2a plus adefovir or peginterferon alfa-2a alone having negative results on HDV-RNA tests; none of the patients receiving adefovir alone had negative results. A decline in HBsAg levels of more than 1 log10 IU per milliliter from baseline to week 48 was observed in 10 patients in the first group, 2 in the second, and none in the third (P<0.001 for the comparison of the first and third groups and P=0.01 for the comparison of the first and second). Treatment with peginterferon alfa-2a for 48 weeks, with or without adefovir, resulted in sustained HDV RNA clearance in about one quarter of patients with HDV infection. (Funded by Hep-Net [the German Network of Excellence on Viral Hepatitis] and others; Current Controlled Trials number, ISRCTN83587695.)

1 June 2016 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
MMMichael Manns
Michael Manns
DSDidier Samuel
Didier Samuel
EGEdward J Gane
Edward J Gane
DMDavid Mutimer
David Mutimer
GMGeoff McCaughan
Geoff McCaughan
XFXavier Forns
Xavier Forns

1 October 2010 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
MMMichael Manns
Michael Manns
MWMarek Woynarowski
Marek Woynarowski
WKWolfgang Kreisel
Wolfgang Kreisel
YLYoav Lurie
Yoav Lurie
CRChristian Rust
Christian Rust
CSChristian P. Strassburg
Christian P. Strassburg